Larimar Therapeutics (LRMR) Net Cash Flow: 2013-2020
Historic Net Cash Flow for Larimar Therapeutics (LRMR) over the last 7 years, with Dec 2020 value amounting to -$33.2 million.
- Larimar Therapeutics' Net Cash Flow fell 635.91% to -$33.2 million in Q4 2020 from the same period last year, while for Dec 2020 it was $68.5 million, marking a year-over-year increase of 2121.79%. This contributed to the annual value of $5.7 million for FY2024, which is 4968.38% up from last year.
- As of Q4 2020, Larimar Therapeutics' Net Cash Flow stood at -$33.2 million, which was down 191.77% from -$11.4 million recorded in Q3 2020.
- In the past 5 years, Larimar Therapeutics' Net Cash Flow ranged from a high of $113.1 million in Q2 2020 and a low of -$33.2 million during Q4 2020.
- Over the past 3 years, Larimar Therapeutics' median Net Cash Flow value was $2.0 million (recorded in 2019), while the average stood at $6.1 million.
- Examining YoY changes over the last 5 years, Larimar Therapeutics' Net Cash Flow showed a top increase of 1,221.40% in 2020 and a maximum decrease of 635.91% in 2020.
- Larimar Therapeutics' Net Cash Flow (Quarterly) stood at $7.5 million in 2016, then skyrocketed by 188.13% to $21.6 million in 2017, then crashed by 80.59% to $4.2 million in 2018, then slumped by 207.54% to -$4.5 million in 2019, then plummeted by 635.91% to -$33.2 million in 2020.
- Its Net Cash Flow stands at -$33.2 million for Q4 2020, versus -$11.4 million for Q3 2020 and $113.1 million for Q2 2020.